ICT-109

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameICT-109
Drug Alias Nameanticancer monoclonal antibodies (ImmunoCellular)ICT-109
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 6 inhibitorsCarcinoembryonic antigen related cell adhesion molecule 5 antagonists
TargetsCarcinoembryonic antigen related cell adhesion molecule 5Carcinoembryonic antigen related cell adhesion molecule 6
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMolecular Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMolecular TherapeuticsImmunocellular Therapeutics Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A